Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Cancer Pain × resiniferatoxin × Clear all

Phase

Phase 3 1 Phase 2 1 Phase 1/2 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Pain, Intractable 1 Pain 1 Cancer Pain 1

Interventions

Morphine 6 nabiximols 3 Oxycodone 2 Methadone 2 Hydromorphone 2 Fentanyl 2 Acetaminophen 2 tanezumab 1 resiniferatoxin 1 naloxegol 1 Tapentadol 1 Sugars 1 Standard of Care 1 Lidocaine 1 Inosine Monophosphate 1 Donepezil 1 6'-fluoro-4',9'-dihydro-N,N-dimethyl-4-phenylspiro(cyclohexane-1,1'(3'H)-pyrano(3,4-b)indol)-4-amine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04572776 2021-11-09

Phase 3 Study to Assess Resiniferatoxin vs Standard of Care for the Treatment of Intractable Cancer Pain

Sorrento Therapeutics, Inc.

Phase 3 Withdrawn

Cancer Pain, Pain, Pain, Intractable

Data powered by HemOnc (CC BY 4.0) Colophon ⚡